Preventive Medicine: Screening for STIs & HIBC to Prevent STIs

May 9th, 2018 - Find-A-Code™
Categories:   CPT® Coding   HCPCS Coding   Preventive Medicine Service  
0 Votes - Sign in to vote or comment.

Screening for STIs and High Intensity Behavioral Counseling (HIBC) to Prevent STIs

Procedure Codes
86592: Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)
86593: Syphilis test, non-treponemal antibody; quantitative
86631: Antibody; Chlamydia
86632: Antibody; Chlamydia, IgM
86780: Antibody; Treponema pallidum
87110: Culture, chlamydia, any source
87270: Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis
87320: Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Chlamydia trachomatis
87340: Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)
87341: Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization
87490: Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique
87491: Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique


87492: Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification
87590: Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique
87591: Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique
87800: Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique
87801: Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique
87810: Infectious agent antigen detection by immunoassay with direct optical observation; Chlamydia trachomatis
87850: Infectious agent antigen detection by immunoassay with direct optical observation; Neisseria gonorrhoeae
96150: Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; initial assessment
96152: Health and behavior intervention, each 15 minutes, face-to-face; individual
96153: Health and behavior intervention, each 15 minutes, face-to-face; group (2 or more patients)
G0445: Semiannual high intensity behavioral counseling to prevent STIs, individual, face-to-face, includes education skills training & guidance on how to change sexual behavior, 30 minutes

Additional Information
G0445, 96150-96153, 86631-86632, 87110, 87270, 87320, 87490-87491, 87810, 87590-87591, 87850, 87800, 86592-96593, 86780, 87340-87341

  • Coverage is indicated for beneficiaries that meet the following criteria:
    • Sexually active adolescents and adults at increased risk for STIs
    • Referred by a primary care provider
    • Services provided by an eligible primary care provider in a primary care center

ICD-10-CM
G0445: No specific diagnoses
96150-96153, 86631-86632, 87110, 87270, 87320, 87490-87491, 87810, 87590-87591, 87850, 87800, 86592-96593, 86780, 87340-87341: Varies widely, consult your payer

Frequency
G0445: Twice annually
96150-96153, 86631-86632, 87110, 87270, 87320, 87490-87491, 87810, 87590-87591, 87850, 87800, 86592-96593, 86780, 87340-87341: Varies widely, consult your payer


Find-A-Code™ - Preventive Services - The information in this document does not guarantee payment or that included codes meet applicable qualifications as preventive services for all insurances and insurance plans, please consult your payer.


###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

Delving Into the 360 Assessment Fraud Complaint
November 17th, 2021 - Jessica Hocker, CPC, CPB
The Department of Justice is pursuing claims of healthcare fraud against Cigna Health-Spring Medicare Advantage plan based on how they used data from their 360 Program in 2012. A review of the allegations may help other payers avoid similar accusations.
Lessons Learned from a RADV Audit Report
November 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
If given an opportunity to know ahead of time the questions that would be asked of you in an upcoming interview or quiz, it is likely the outcome would be significantly better than if you were surprised by the questions. This same concept may be applied to audits of risk ...
Changes in RPM for 2021! Now, Wait for it... New RTM Codes for 2022
November 11th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Remote physiologic monitoring and clinical data monitoring is a relatively new concept thriving and growing as an essential component for telehealth services. According to global consumer trends, a company called Dynata reported, "Among the 39% of people who consulted a healthcare professional, two-thirds used telemedicine, many of them for the first time ...
Reporting and Auditing Drug Testing Services
November 9th, 2021 - Aimee Wilcox CPMA, CCS-P, CST, MA, MT
Drug testing is a common medical service used to manage prescription medications, verify someone is not taking illegal substances or too much of a prescribed substance, and monitor for toxicity and therapeutic dosing. It is customary for patients in treatment programs for chronic pain management or substance use disorders (SUD) to undergo random urine drug testing (UDT) or urine drug screening (UDS) as part of their individual treatment plan. Drug testing is regulated by federal and state laws (e.g., OSHA, CLIA), which must be carefully adhered to.
Understanding ASCs and APCs: Indicators and Place of Service
October 28th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
The decision regarding the most appropriate care setting for a given surgical procedure is determined by the physician based on the patient's individual clinical needs and preferences. Of course, there is a difference in reimbursement, and the billing depends on where the procedure took place, such as an office setting, inpatient ...
Are You Keeping up with the Official ICD-10-CM Guideline Changes for COVID-19?
October 25th, 2021 - Wyn Staheli, Director of Research
The COVID-19 public health emergency (PHE) has made it interesting and challenging for organizations to keep an eye on the evolving changes to the ICD-10-CM Official Guidelines for Coding and Reporting. Have you been keeping up with these changes?
Is Your Organization Ready to Deal with Provider Relief Fund (PRF) Audit Contractors?
October 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Audits are currently underway to verify the monies distributed through the CARES Act were warranted and properly used by those organizations that received them. The federal government has contracted with financial institutions such as KPMG and PricewaterhouseCoopers, among others, to perform these audits referred to as Provider Relief Fund (PRF) audit contractors, funded with monies from the very same program. There were four phases of funding disbursements with phase 1 audits beginning in September. How ready are you to be audited?



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association